Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).
Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Sarmad Zahoor
- Target Recruit Count
- 90
- Registration Number
- NCT05573958
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05546957
- Locations
- 🇬🇧
LabCorp CRU, Leeds, West Yorkshire, United Kingdom
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
- Conditions
- Patent Foramen OvaleMigraine
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05546320
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, Beijing, China
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
- Conditions
- Anticoagulant-induced BleedingVenous ThromboembolismVenous ThrombosesPulmonary Embolism
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Target Recruit Count
- 58
- Registration Number
- NCT05515120
- Locations
- 🇲🇽
Instituto Mexicano Del Seguro Social, Metepec, Estado De Mexico, Mexico
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
- Conditions
- Anticoagulant Therapy
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Doasense GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT05491460
- Locations
- 🇩🇪
Clincial Research Serivces, Mannheim, Germany
Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
- Conditions
- Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 550
- Registration Number
- NCT05487950
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
- Conditions
- Venous ThromboembolismCancerTreatment of Venous Thromboembolism in Cancer Patients
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2437
- Registration Number
- NCT05461807
- Locations
- 🇩🇪
Bayer, Wuppertal, Germany
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
- Conditions
- ArthroplastyVenous Thromboembolism
- Interventions
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Chiayi Christian Hospital
- Target Recruit Count
- 178
- Registration Number
- NCT05449327
- Locations
- 🇨🇳
Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 10
- Registration Number
- NCT05410275
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 700
- Registration Number
- NCT05399277
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.